MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
60.67
+3.17
+5.51%
After Hours: 61.14 +0.47 +0.78% 17:09 05/20 EDT
OPEN
58.68
PREV CLOSE
57.50
HIGH
60.91
LOW
56.74
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
91.00
52 WEEK LOW
9.54
MARKET CAP
3.66B
P/E (TTM)
-25.3902
1D
5D
1M
3M
1Y
5Y
1D
Oruka SVP Finance Arjun Agarwal sells common shares worth $599,263.29
PUBT · 2d ago
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
TipRanks · 2d ago
Weekly Report: what happened at ORKA last week (0511-0515)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)
TipRanks · 5d ago
Oruka Therapeutics CMO Joana Goncalves disposes 7,000 shares for $435,915.36
PUBT · 5d ago
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)
TipRanks · 6d ago
Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 6d ago
Oruka Therapeutics Price Target Maintained With a $151.00/Share by BTIG
Dow Jones · 6d ago
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.